Investors and Media

Idera is advancing to the clinic in autoimmune diseases and certain genetically defined forms of B-cell lymphoma: activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia and others. Its lead drug candidate, IMO-8400, is designed to modulate immune responses through Toll-like receptors (TLRs).

Recent News

Oct 07, 2016Idera Pharmaceuticals Announces Pricing of Public Offering of Common StockRead MoreOct 05, 2016Idera Pharmaceuticals Announces Proposed Public Offering of Common StockRead MoreSep 27, 2016Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics SocietyRead More


September 26, 2016 at 9:00 a.m. ETIdera Pharmaceuticals, Inc. Corporate Conference Call
August 16, 2016 at 12:45 p.m. ETIdera at the 2016 Wedbush PacGrow Healthcare Conference

Upcoming Events

There are currently no events scheduled.


September 26, 2016
Idera Pharmaceuticals Corporate Overview
September 26, 2016
IMO-2125 Phase 1/2 Clinical Trial Data Update
Data provided by Nasdaq. Minimum 15 minutes delayed.